Biolabs International LLC Announces Its Successful Launch of SpeedySwab™ Rapid COVID-19 + FLU A&B Antigen Self-Test and Their New AI-Driven Diagnostics App Amid the Most Severe Flu Season Since 2009
SAN DIEGO, Feb. 28, 2025 /PRNewswire/ -- The United States is currently facing its most severe flu season since 2009, according to the latest data from the Centers for Disease Control and Prevention (CDC). The CDC has classified this season as "high severity" for all age groups—marking the first time a flu season has received this designation since 2017–18.
The 2024–25 influenza season has had a significant impact on public health, with the latest CDC Influenza Surveillance Report for the week ending February 8, 2025, revealing:
- 29 million flu-related illnesses
- 370,000 hospitalizations
- 16,000 deaths
Additionally, during the most recent reporting week, 31.6% of tested individuals were positive for influenza, and 50,382 people were hospitalized due to flu-related complications.
Biolabs International LLC Expands Access to Rapid Flu & COVID Testing In response to this critical public health challenge, Biolabs International LLC is proud to introduce its SpeedySwab™ Rapid COVID-19 + FLU A&B Antigen Self-Test, an at-home diagnostic solution designed to help detect and mitigate the spread of influenza and COVID-19.
Biolabs International has also redesigned its retail packaging to optimize in-store placement and visibility. The newly assembled-in-the-USA packaging is crafted for seamless integration into retail spaces, pharmacy shelves, and medical distribution networks.
"Our 18-month shelf life provides an additional six months of usability compared to other leading brands, making SpeedySwab™ the superior choice for families and healthcare providers during this challenging flu season," said Gino Ajodani, President of Biolabs International LLC.
AI-Powered Diagnostics: The Future of At-Home Testing
Biolabs International is also launching AI-integrated diagnostic solutions that enhance testing accuracy and efficiency. These connected diagnostic tools leverage real-time data management and artificial intelligence to streamline test result validation and improve decision-making.
"This technology represents a major advancement in precision diagnostics," Ajodani added. "By seamlessly integrating AI, we empower consumers and healthcare professionals with faster, more reliable, and actionable insights—ensuring better health outcomes."
Commitment to U.S.-Based Manufacturing & Supply Chain Expansion
As part of its ongoing commitment to domestic manufacturing and supply chain sustainability, Biolabs International has expanded its U.S.-based operations to support increasing demand for high-quality, reliable diagnostic solutions.
With SpeedySwab™ products now available through major retailers including Walgreens, Kroger, Ralphs, Amazon, and BevMo, Biolabs International is poised for continued growth throughout 2025.
About Biolabs International LLC
Biolabs International LLC is the exclusive distributor of Watmind USA™, manufacturer of the SpeedySwab™ brand tests. This exclusivity spans across the United States, Mexico, Canada, South America, and Europe. Since the onset of the pandemic, Biolabs International LLC has been a leader in innovative diagnostic solutions, developing cutting-edge software and distributing rapid antigen tests through major retail and healthcare networks.
In partnership with SafeHealth Systems, Biolabs International has developed AI-powered healthcare applications, including telehealth-integrated testing solutions. The company continues to expand its portfolio, with additional AI-driven healthcare innovations set for release in early 2025.
For media inquiries, please contact:
Biolabs International LLC
Info@biolabsinternational.net
800-440-4580
View original content to download multimedia:https://www.prnewswire.com/news-releases/biolabs-international-llc-announces-its-successful-launch-of-speedyswab-rapid-covid-19--flu-ab-antigen-self-test-and-their-new-ai-driven-diagnostics-app-amid-the-most-severe-flu-season-since-2009-302387982.html
SOURCE Biolabs International LLC